Roche (Roche Holding AG) is a global healthcare company headquartered in Basel, Switzerland, focused on the research, development, and manufacturing of pharmaceuticals and diagnostics. The group operates through two core divisions—Pharmaceuticals and Diagnostics—and includes subsidiaries such as Genentech in the United States and Chugai in Japan.
For the chemical and life sciences value chain, Roche develops small‑molecule medicines and active pharmaceutical ingredients (APIs) alongside a broad portfolio of biologics, including monoclonal and bispecific antibodies. Its capabilities span process chemistry, analytical development, scale‑up, and GMP manufacturing, as well as large‑scale cell culture, purification, and fill‑finish operations. The Diagnostics division provides in vitro diagnostic systems, reagents, and molecular testing technologies. Roche’s therapeutic focus areas include oncology, immunology, infectious diseases, neuroscience, and ophthalmology. The company maintains a global R&D and manufacturing network and emphasizes regulatory compliance, quality, and reliable supply across its operations.
Also known as Roche Group, Roche Holding AG, Roche Diagnostics GmbH, Roche Diagnostics, F. Hoffmann-La Roche, and Roche Pharmaceuticals.
chemXplore tracks 3 projects involving Roche, of which 2 are active.
Roche's role on them: Owner, Investor / Financier, and Developer.
1 new construction and 1 expansion.
Contractors and licensors are recorded on 1 of these 2 projects For subscribers
Interim analysis shows significant, clinically meaningful 24‑hour UPCR reduction at 37 weeks; blinded study continues to the eGFR endpoint at week 105.
Phase III interim data show significant proteinuria reduction at 37 weeks; drug targets liver-derived factor B via monthly subcutaneous dosing; blinded follow-up continues to week 105 eGFR.
Once‑weekly dual GLP‑1/GIP enicepatide cut HbA1c up to 2.65% and body weight 15.5% at 48 weeks in Phase II; safety aligned with the incretin class.
Continuous ranibizumab delivery via the Contivue refillable implant offers an alternative to monthly intravitreal injections, with as few as two treatments per year.
CHMP backs ocrelizumab for relapsing MS in patients aged 10 and older after Phase III showed stronger lesion suppression and comparable relapse control versus fingolimod.
Allston hub will focus on cardiovascular, renal and metabolic R&D, combine discovery-to-clinical work with AI and data science, and is part of a USD 50bn US investment programme.
Interim analysis shows a significant progression‑free survival benefit versus rituximab+lenalidomide in second‑line or later relapsed/refractory follicular lymphoma; safety as expected.
Phase III CELESTIMO interim analysis showed a statistically significant, clinically meaningful PFS benefit versus rituximab+lenalidomide; OS immature; safety consistent with known profiles.
By country, the most active first. active / all projects
